| Identification | Back Directory | [Name]
Lopinavir-d8 | [CAS]
1322625-54-6 | [Synonyms]
LOPINAVIR-D8
2,3,4,4,4-pentadeuterio-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-2-(2-oxo-1,3-diazinan-1-yl)-3-(trideuteriomethyl)butanamide | [Molecular Formula]
C37H40D8N4O5 | [MOL File]
1322625-54-6.mol | [Molecular Weight]
636.85 |
| Chemical Properties | Back Directory | [Melting point ]
>96°C (dec.) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
Off-White to Pale Beige | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Description]
Lopinavir-d8 is intended for use as an internal standard for the quantification of lopinavir by GC- or LC-MS. Lopinavir is a potent HIV-1 protease inhibitor (Ki = 1.3 pM for wild-type enzyme). It inhibits the replication of clinical isolates of HIV-1 (EC50s = 5-52 nM). Lopinavir reduces the infectious virus yield and viral RNA copy numbers in the culture supernatant of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC50s = 26.63 and 26.10 μM, respectively). It reduces lung and kidney viral load, bronchointerstitial pneumonia, and pulmonary inflammatory cell infiltration in a marmoset model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection when administered in combination with ritonavir . | [Uses]
A labelled selective HIV protease inhibitor. An analogue of Ritonavir. Antiviral. It is a COVID19-related research product. |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|